|
Jeremy Curnock Cook founded BML in February 2001, following his time at Rothschild. During his thirteen years at Rothschild, Mr. Curnock Cook created and led the Rothschild Bioscience Unit - the international and multidisciplinary team responsible for the investment advisory and management of a number of funds, including the early stage focused Biotechnology Investments Limited (BIL) and the mid stage focused International Biotechnology Trust plc (IBT).
Mr. Curnock Cook founded the International Biochemicals Group in 1975, which was sold to Royal Dutch Shell in 1985; he continued to serve as Managing Director until 1987. From 1987 to 2000, he was a Director of Rothschild Asset Management Limited and was responsible for the Rothschild Bioscience Unit. Mr. Curnock Cook is Chairman of the Board of Targeted Genetics Inc., in Seattle and Inflazyme Pharmaceuticals Ltd. in Vancouver. Mr. Curnock Cook is also a member of the board of directors of Sirna Therapeutics Inc. as well as other companies in the United Kingdom, Canada and Australia. | 